These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 34314018)

  • 21. Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.
    Sheikh S; Lebel E; Trudel S
    Future Oncol; 2020 Dec; 16(34):2783-2798. PubMed ID: 32875817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.
    Shragai T; Magen H; Lavi N; Gatt M; Trestman S; Zektser M; Ganzel C; Jarchowsky O; Berger T; Tadmor T; Leiba M; Hertzog-Tzarfaty K; Horowitz N; Shapira M; Varssano D; Berger Y; Frenkel S; Krauthammer M; Avivi I; Luttwak E; Cohen YC;
    Br J Haematol; 2023 Jan; 200(1):45-53. PubMed ID: 36205375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
    Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Ribas de Almeida AC; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Pitombeira de Lacerda M; Aparecida Martinez G; Sureda Balarí AM; Sandhu I; Cerchione C; Ganly P; Dimopoulos M; Fu C; Garg M; Abdallah AO; Oriol A; Gatt ME; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Pirooz N; McKeown A; McNamara S; Zhou X; Nichols M; Lewis E; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Opalinska J; Mateos MV;
    N Engl J Med; 2024 Aug; 391(5):393-407. PubMed ID: 38828933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
    Talbot A; Bobin A; Tabone L; Lambert J; Boccaccio C; Deal C; Petillon MO; Allangba O; Agape P; Arnautou P; Belkhir R; Cailleres S; Chaoui D; Chrétien ML; Decaux O; Schulmann S; Frenzel L; Gastaud L; Huart A; Hulin C; Karlin L; Laribi K; Le Calloch R; Lenain P; Macro M; Manier S; Montes L; Moreau S; Moreau P; Morel V; Norwood J; Piocelle FO; Perrot A; Pica GM; Rey P; Schmitt A; Stoppa AM; Tiab M; Touzeau C; Vidal V; Vignon M; Vincent L; Van De Wyngaert Z; Zarnitsky C; Kerbouche N; Paka P; Leleu X; Arnulf B; Avet-Loiseau H; Du Myélome IIF
    Haematologica; 2023 Oct; 108(10):2774-2782. PubMed ID: 37078253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
    Offidani M; Corvatta L; Morè S; Olivieri A
    Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial.
    Trudel S; McCurdy A; Louzada ML; Parkin S; White D; Chu MP; Kotb R; Mian H; Othman I; Su J; Khan A; Gul E; Reece D
    Nat Med; 2024 Feb; 30(2):543-551. PubMed ID: 38177852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
    Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
    Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Belantamab mafodotin concentration-QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM-1 and -2 studies.
    Jewell RC; Mills RJ; Farrell C; Visser SAG
    Br J Clin Pharmacol; 2024 Oct; 90(10):2571-2581. PubMed ID: 38924122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.
    Lassiter G; Bergeron C; Guedry R; Cucarola J; Kaye AM; Cornett EM; Kaye AD; Varrassi G; Viswanath O; Urits I
    Curr Oncol; 2021 Jan; 28(1):640-660. PubMed ID: 33494319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
    Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
    Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.
    Weisel K; Krishnan A; Schecter JM; Vogel M; Jackson CC; Deraedt W; Yeh TM; Banerjee A; Yalniz F; Nesheiwat T; Van Sanden S; Diels J; Valluri S; Usmani SZ; Berdeja JG; Jagannath S; Martin T
    Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):690-701. PubMed ID: 35764490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma.
    Ntanasis-Stathopoulos I; Malandrakis P; Fotiou D; Migkou M; Theodorakakou F; Roussou M; Eleutherakis-Papaiakovou E; Spiliopoulou V; Kastritis E; Terpos E; Dimopoulos MA; Gavriatopoulou M
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma.
    Rathi C; Collins J; Struemper H; Opalinska J; Jewell RC; Ferron-Brady G
    CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):851-863. PubMed ID: 34076364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real-world setting: The ALFA study.
    Roussel M; Texier N; Nael V; Bitetti J; Paka P; Kerbouche N; Sail L; Colin X; Leleu X
    Eur J Haematol; 2024 Sep; 113(3):310-320. PubMed ID: 38722078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma.
    Baines AC; Ershler R; Kanapuru B; Xu Q; Shen G; Li L; Ma L; Okusanya OO; Simpson NE; Nguyen W; Theoret MR; Pazdur R; Gormley NJ
    Clin Cancer Res; 2022 Nov; 28(21):4629-4633. PubMed ID: 35736811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Belantamab mafodotin for relapsed or refractory multiple myeloma.
    Gil-Sierra MD; Briceño-Casado MDP
    J Oncol Pharm Pract; 2022 Sep; 28(6):1375-1380. PubMed ID: 35306910
    [No Abstract]   [Full Text] [Related]  

  • 37. Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
    Shah A; Tosh JC; Ambavane A; Nikolaou A; Hogea C; Samyshkin Y; Gorsh B; Maiese EM; Wang F
    Clinicoecon Outcomes Res; 2021; 13():789-800. PubMed ID: 34531667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study.
    Cardellino A; Correll JR; Martin M; Gorsh B; Sapra S; Popat R
    Front Oncol; 2023; 13():1274659. PubMed ID: 38144529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP).
    Alegre A; Benzo G; Alonso R; Martínez-López J; Jimenez-Ubieto A; Cuéllar C; Askari E; Prieto E; Aláez C; Aguado B; Velasco A; Krsnik I; Bocanegra A; Llorente L; Muñoz-Linares C; Morales A; Giménez E; Iglesias R; Martínez-Chamorro C; Alonso A; Jiménez-Montes C; Blanchard MJ;
    Oncol Ther; 2023 Mar; 11(1):83-96. PubMed ID: 36509945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
    Martin TG; Shah N; Richter J; Vesole DH; Wong SW; Huang CY; Madduri D; Jagannath S; Siegel DS; Biran N; Wolf JL; Parekh S; Cho HJ; Munster P; Richard S; Ziti-Ljajic S; Chari A
    Cancer; 2021 Jun; 127(11):1816-1826. PubMed ID: 33735504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.